Precision AI
Solutions

Precision AI Solutions

The Oncology CoPilot Platform equips oncologists, diagnostic laboratories and research organizations with cutting-edge AI-powered drug-cancer biological network analysis software. It delves deep into the intricate tumor biology of every cancer patient, facilitating well-informed treatment decisions. By analyzing high-throughput gene expression profiling data, the platform conducts thorough evaluations of tumors, encompassing molecular subtyping, microenvironment, and immune response assessments. It then generates personalized therapy options, ranked by the probability of drug response. This empowers oncologists to craft precise and effective treatment plans tailored to each individual patient, across all cancer types, with access to over 240 drug options.

Our focus today

Cancer is the broadest term describing myriad ailments. There is no single cure. Each cancer type has its own unique challenges and treatment options.

Pancreatic Cancer

The challenges of Pancreatic Cancer

Pancreatic cancer is a complex and aggressive disease with limited treatment options. Timelines are compressed for myriad reasons, from late stage discovery to the aggressive nature of the disease's progression. The standard of care today typically involves beginning a therapy regimen with limited information. Therapy options are limited and generally must be started before more comprehensive test results are made available.

How we're tackling these issues

Precision AI Solutions has partnered with Cellentia to expedite tumor analysis and reduce RNAseq processing time. We can turn the time between biopsy and test result from weeks into days. The Oncology CoPilot platform can analyze these results and provide personalized treatment recommendations with greater efficacy and minimizing patient risk. These assessments have a global impact as well. Better therapy recommendations don't just benefit the individual patient, but also the entire population. As we learn more about what works, research will yield new therapy recommendations by having a clearer understanding of what is effective and how to keep patients comfortable.

Triple Negative Breast Cancer (TNBC)

Why TNBC stands out amongst breast cancer diagnoses

Breast cancer is one of the most common cancers. A litany of research and treatment options exist for many breast cancer subtypes. Triple Negative Breast Cancer (TNBC) is a particularly aggressive form of breast cancer that lacks the three most common types of receptors known to fuel most breast cancer growth. This makes it more difficult to treat, as many of the targeted therapies used for other breast cancers are ineffective against TNBC. As a result, TNBC often requires more aggressive treatment approaches, such as chemotherapy, which can have significant side effects and impact on quality of life.

What we hope to bring to the table

Oncology CoPilot's unique approach to tumor cell analysis goes beyond the traditional scope of using biomarkers and select coding genes to identify effective therapies. Instead, we leverage the full breadth of the molecular landscape to identify the most effective therapies for each patient, analyzing all genes.

How it works

Sample Collection

A tissue or blood sample is collected from the patient for analysis.

Gene Expression Profiling

The sample undergoes high-throughput gene expression profiling to capture the molecular characteristics of the tumor.

Data Analysis

The gene expression data is analyzed using advanced AI algorithms to identify key biological networks and pathways associated with the tumor.

Therapy Recommendation

Based on the analysis, the platform generates personalized therapy options ranked by their predicted efficacy for the individual patient.

Oncologist Review

Oncologists review the recommended therapies and make informed treatment decisions tailored to the patient's unique tumor biology.

Step 01